Risto Lammintausta, M.D., Ph.D. Pharmacology and Clinical Pharmacology. He has over 30 years of drug development experience in different positions of R&D management, from Farmos Group, Orion Pharma, Hormos Medical and QuatRx. During his career, five new compound discoveries have been launched to global markets, including Ospemifene. In 2013, he co-founded and became CEO of Forendo Pharma. Risto has served as board member of multiple biopharma companies and has had positions of trust in associations of Finnish Bioindustry, Chemical Industry and Pharma Industry.
Janne Komi, M.D., Ph.D., has over 10 years of experience in the pharmaceutical industry and has held various positions ranging from R&D lead roles in early drug discovery to clinical development both in Finland (Hormos Medical) and in the US (QuatRx Pharmaceuticals Company). In addition, Dr. Komi has over 5 years of regulatory experience at the Finnish Medicines Agency (Fimea) and Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA).
Maarit Merla, Head of Business Development, MSc (Econ), eMBA, is a life science business professional, with over 17 years of international experience in the medical device, diagnostics and pharmaceutical industries. She has been responsible for several operational and R&D functions, marketing and business development, working in global teams across Europe, Middle East and Africa, North America and Asia.
Maarit joined Forendo Pharma in August 2015. In her Business Development role at Forendo, she is responsible for fundraising, licensing, partnering and marketing activities.
Endometriosis is a chronic condition that affects up to 10% of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have limitations in efficacy or cause harmful side effects. They often lead to systemic estrogen depletion, with known safety issues on bone mineral density and menopausal symptoms. There is no known cure for the disease. Download a pdf about endometriosis »
Forendo Pharma has developed a potential new treatment for endometriosis based on inhibition of the HSD17B1 enzyme, a novel drug target for tissue specific regulation of hormone activity. Proof of efficacy for this novel mechanism has been demonstrated in primate model of endometriosis. The clinical compound FOR-6219 inhibits the conversion of low potency estrone into highly potent estradiol in endometriotic tissues. The most important expected differentiator of FOR-6219 compared to currently available treatments is its selective activity and the ability to act locally in the target tissues, without impacting systemic hormone levels. This selective activity allows a safe and well tolerated, long term treatment opportunity for endometriosis. FOR-6219 is currently in Phase I clinical development
The DUAL HSD Inhibitor compounds, currently in discovery phase, combine two mechanisms of action whereby estrogen inhibition and direct anti-inflammatory effect can be combined locally in target tissues, without affecting systemic hormones. The DUAL HSD Inhibitor program was initiated in 2016 and Forendo is planning to select the product candidate for further development in 2019. These novel compounds have broad indication opportunities in endometriosis and other gynecological conditions.
Fispemifene is a novel selective estrogen receptor modulator (SERM), with a unique tissue specific pharmacological profile. In the completed Phase I and II studies Fispemifene has been safe and well tolerated in over 250 men exposed so far.
Fispemifene has potential in 3 different indication areas of male urological conditions
Proven ability to increase testosterone. By diminishing the negative feedback of estrogen at the level of hypothalamus/pituitary gland, Fispemifene has shown to increase production of LH and subsequently endogenous testosterone levels.
Demonstrated antiestrogenic and anti-inflammatory effects in the lower urinary tract and prostate in preclinical models. The increase in systemic testosterone levels with the antiestrogenic effect in selective tissues provides novel approach to treat LUTS and chronic prostatitis.
Potential to increase the efficacy of androgen deprivation therapy (ADT), as a combination drug, by blocking the estrogen action in the prostate. As testosterone is blocked by ADT, there is no risk of unwanted testosterone level increase. Fispemifene is expected to prolong the duration of ADT treatment, thereby offering longer progression free survival and overall survival to prostate cancer patients.
Forendo is currently under a Letter of Intent, aiming for a global licensing agreement of the Fispemifene asset.
Please let us know how we can provide you with more information about our company or products. Forendo Pharma is located in the 7th floor, staircase B of Pharmacity building, close to the Kupittaa railway station (Turku–Helsinki connection) and the Helsinki motorway (E18).